pharmexec.com
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus placebo. This may affect treatment discussions between patients and clinicians.
Adults with moderate-to-severe Crohn disease, patients considering biologic therapy, clinicians treating IBD, and researchers following new IBD drug approvals.
What To Know
FDA approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn disease in adults based on results from the Phase III VIVID-1 trial.
The article reports one-year results showing higher rates of clinical remission and endoscopic response with Omvoh versus placebo, describes the IV induction and SC maintenance dosing regimen used in the trial, notes common adverse events observed, and mentions an ongoing open-label extension (VIVID-2).
Omvoh is a biologic (mirikizumab) now approved for both ulcerative colitis and Crohn disease. The VIVID-1 trial used a 900 mg IV induction at weeks 0, 4, and 8, followed by 300 mg SC every 4 weeks starting at week 12; the FDA decision cited clinical remission and endoscopic response at one year as primary endpoints.
Safety findings in the Crohn’s studies were reported as consistent with the drug’s prior ulcerative colitis profile, with common events including upper respiratory infections, injection-site reactions, headache, arthralgia, and elevated liver tests.
For people tracking new treatment options: this approval adds another biologic class option for adults with moderate-to-severe Crohn disease and may be relevant for patients who have not responded to other therapies. Ongoing VIVID-2 will provide longer-term safety and efficacy data.
This is a regulatory approval story based on Phase III VIVID-1 results and company/release citations; full prescribing information, longer-term data from the VIVID-2 extension, and independent peer-reviewed publications should be consulted for detailed efficacy and safety characteristics.
The article summarizes press-release information and trial endpoints rather than presenting new independent analyses.
